^
    3years
    This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions (clinicaltrials.gov)
    P1, N=0, Withdrawn, Skyline Biosciences | N=24 --> 0 | Not yet recruiting --> Withdrawn
    Clinical • Enrollment change • Trial withdrawal
    |
    CRP (C-reactive protein)
    |
    SBS-101